{"id":"NCT03621280","sponsor":"Cortendo AB","briefTitle":"Open-label Treatment in Cushing's Syndrome","officialTitle":"An Open-label Extension Study of Levoketoconazole (2S,4R-ketoconazole) in the Treatment of Endogenous Cushing's Syndrome","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-07","primaryCompletion":"2022-12-31","completion":"2022-12-31","firstPosted":"2018-08-08","resultsPosted":"2025-06-19","lastUpdate":"2025-06-19"},"enrollment":51,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Cushing Syndrome","Cushing Disease"],"interventions":[{"type":"DRUG","name":"Levoketoconazole","otherNames":["COR-003"]}],"arms":[{"label":"Levoketoconazole","type":"EXPERIMENTAL"}],"summary":"This is a long-term, open-label extension study of levoketoconazole in participants with endogenous Cushing's Syndrome.","primaryOutcome":{"measure":"Proportions of Participants With Mean Urinary Free Cortisol (mUFC) Categorization Based on Upper Limit of Normal (ULN)","timeFrame":"From parent study Baseline to final study visit or up to a maximum of 3 years, whichever comes first.","effectByArm":[{"arm":"All Participants","deltaMin":0,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":4},"locations":{"siteCount":30,"countries":["United States","Bulgaria","France","Greece","Hungary","Israel","Italy","Netherlands","Poland","Romania","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":20,"n":51},"commonTop":["Nausea","Hypertension","Hypokalaemia","Headache","Fatigue"]}}